Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Germans Trias i Pujol Hospital)
- Development stage
- Unknown
- Lead developer
- Hospital Universitari Germans Trias i Pujol
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational autologous cell therapy consisting of mesenchymal stem cells (MSCs) derived from the patient's own bone marrow, developed and studied by the Germans Trias i Pujol Hospital. The therapy is primarily indicated for relapsing-remitting multiple sclerosis (RRMS). The treatment process involves harvesting bone marrow from the patient, expanding the MSCs in a controlled culture environment, and then re-administering the cells via intravenous infusion. The mechanism of action is multifaceted, involving immunomodulation to suppress the autoimmune inflammatory response that damages the central nervous system, as well as potential neuroprotective effects through the secretion of various growth and neurotrophic factors that may promote tissue repair and remyelination.
- Other names
- BM-MSCautologous BM-MSCautologous bone marrow-derived mesenchymal stem cellsMESEMS therapy
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Germans Trias i Pujol Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Germans Trias i Pujol Hospital).